Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 May;135(5):860-868.
doi: 10.1111/bju.16651. Epub 2025 Jan 28.

Tumour size is associated with growth rates of >0.5 cm/year and delayed intervention in small renal masses in patients on active surveillance

Maximilian Pallauf  1   2 , Michael Rezaee  1 , Roy Elias  3 , Tina Wlajnitz  1 , Sean A Fletcher  1 , Joseph Cheaib  1 , Khalid Alkhatib  4   5 , Peter Chang  6 , Andrew A Wagner  6 , James M McKiernan  7 , Mohamad E Allaf  1 , Phillip M Pierorazio  4 , Nirmish Singla  1   3
Affiliations
Multicenter Study

Tumour size is associated with growth rates of >0.5 cm/year and delayed intervention in small renal masses in patients on active surveillance

Maximilian Pallauf et al. BJU Int. 2025 May.

Abstract

Objective: To evaluate the association between tumour size and the growth rate (GR) of small renal masses (SRMs) in patients managed by active surveillance (AS).

Materials and methods: We queried the prospective, multi-institutional Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) registry for patients on AS with an imaging interval of ≥6 months, identifying 456 patients. We tracked tumour size over time; a GR >0.5 cm/year was defined as a GR event. We used multivariable recurrent events and time-to-event Cox regression modelling to evaluate the association between tumour size and GR events (primary outcome) and tumour size and delayed intervention (DI; secondary outcome). We tested tumour size as a continuous variable and dichotomised tumour size by predefined (2-cm) and calculated (2.9-cm) cutoffs. We calculated the cutoff using maximally selected rank statistics and time to progression, defined according to the DISSRM registry.

Results: The median (interquartile range) follow-up of patients on AS was 40.1 (26.4-71.2) months, during which 128 patients (28%) had ≥1 GR event, and 80 (18%) underwent DI. Larger tumour size was an independent predictor for GR events and DI when tested as a continuous and a dichotomous variable in multivariable analyses (all P < 0.05). The association was strongest when accounting for the change in tumour size over time and when applying the 2.9-cm cutoff. The study is limited by the mixed tumour pathology inert to SRMs.

Conclusion: Larger tumour size was independently associated with GR events and DI for patients with SRMs on AS. A 2.9-cm cutoff may provide valuable information for patient counselling.

Keywords: active surveillance; carcinoma; growth kinetics; renal cell carcinoma; small renal mass.

PubMed Disclaimer

Conflict of interest statement

Declaration of Interests

None of the contributing authors have any conflict of interest, including specific financial interests, relationships, and affiliations relevant to the subject matter or materials discussed in the manuscript.

References

    1. Patel HD, Gupta M, Joice GA, Srivastava A, Alam R, Allaf ME, et al. Clinical Stage Migration and Survival for Renal Cell Carcinoma in the United States. Eur Urol Oncol. 2019;2(4):343–8. - PubMed
    1. Turner RM, Morgan TM, Jacobs BL. Epidemiology of the Small Renal Mass and the Treatment Disconnect Phenomenon. Urol Clin North Am. 2017;44(2):147–54. - PMC - PubMed
    1. Pierorazio PM, Johnson MH, Ball MW, Gorin MA, Trock BJ, Chang P, et al. Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry. Eur Urol. 2015;68(3):408–15. - PubMed
    1. Campi R, Sessa F, Corti F, Carrion DM, Mari A, Amparore D, et al. Triggers for delayed intervention in patients with small renal masses undergoing active surveillance: a systematic review. Minerva Urol Nefrol. 2020;72(4):389–407. - PubMed
    1. Gorin MA, Rowe SP, Baras AS, Solnes LB, Ball MW, Pierorazio PM, et al. Prospective Evaluation of (99m)Tc-sestamibi SPECT/CT for the Diagnosis of Renal Oncocytomas and Hybrid Oncocytic/Chromophobe Tumors. Eur Urol. 2016;69(3):413–6. - PubMed

Publication types